CANCER AND LEUKEMIA GROUP B

这是一份继续临床研究的更新申请 癌症是CALGB的成员。 纽约医院-康奈尔 医疗中心与北岸大学医院和 附属机构仍然是主要的捐助者， CALGB的科学、临床和行政活动。 我们 多学科的发展反映在我们的临床活动（我们的 集团现在是CALGB研究的主要贡献者）和我们的 参与CALB事务。 领导活动是 反映在我们的行政和科学贡献， CALGB，我们的多学科增长，并在我们的试点和第二阶段， 程序. 我们的目标是以合作的方式参与 设计和进行癌症治疗试验。 在这方面 我们将（1）确定缓解的效果、程度和持续时间 和其他应对措施的执行情况 CALGB，（2）研究自然史，免疫方面， 研究疾病的细胞遗传学和分子生物学 （3）参加试点、第二阶段和多学科 CALGB试验，（4）继续高水平的患者累积， 最近几年的数据收集，（5）继续我们的 积极参与与集团有关的集团活动 科学和集团管理。

This is a renewal application for continuing research in clinical cancer as a member of CALGB. The New York Hospital - Cornell Medical Center together with North Shore University Hospital and affiliated institutions remain a major contributor to the scientific, clinical and administrative activities of CALGB. Our multidisciplinary growth is reflected in our clinical activities (our group is now the leading contributor to CALGB studies) and our participation in CALGB affairs. Leadership activities are reflected in our administrative and scientific contributions to CALGB, our multidisciplinary growth, and in our pilot and phase II programs. Our aims are to participate in a cooperative approach in the design and conduct of therapeutic trials in cancer. In this context we will (1) determine the effect, extent and duration of remission and other responses to treatment of the diseases of concern to CALGB, (2) study the natural history, immunologic aspects, cytogenetics, and molecular biology of the diseases investigated by CALGB, (3) participate in pilot, phase II and multidisciplinary trials of CALGB, (4) continue the high level of patient accrual and data collection of the recent grant years, (5) continue our vigorous participation in Group activities as it pertains to Group science and Group administration.